Skip to main content
Top
Published in: Digestive Diseases and Sciences 11/2011

01-11-2011 | Case Report

Focal Fat Masquerading as Malignancy in the Liver Graft of a Post-Transplant Patient

Authors: Caitlyn M. Patrick, Paul H. Hayashi, Tomasz Kozlowski, Kevin G. Greene, Richard C. Semelka, A. Sidney Barritt IV

Published in: Digestive Diseases and Sciences | Issue 11/2011

Login to get access

Abstract

Background and Aims

Liver failure from non-alcoholic fatty liver disease (NAFLD) is an increasing indication for liver transplant and recurrence of fatty liver in transplanted grafts has been documented. Herein is described an atypical recurrence of steatosis as a de novo focal fatty lesion that mimicked a more ominous cancerous lesion. This presentation of recurrent NAFLD has not previously been described in the literature.

Methods

Chart review.

Results

Biopsy of an atypical lesion was found to be focal fat with surrounding steatohepatitis.

Conclusions

Non-alcoholic fatty liver disease may recur after liver transplant and manifest as a focal fatty lesion. It is important to catalogue the atypical presentations of the increasingly common NAFLD developing in transplanted livers.
Literature
1.
go back to reference Zissen MH, Quon A. Focal fat mimicking multiple hepatic metastases on FDG PET/CT imaging. Eur J Nucl Med Mol Imaging. 2009;36:1527.PubMedCrossRef Zissen MH, Quon A. Focal fat mimicking multiple hepatic metastases on FDG PET/CT imaging. Eur J Nucl Med Mol Imaging. 2009;36:1527.PubMedCrossRef
2.
go back to reference Purandare NC, Rangarajan V, Rajnish A, Shah S, Arora A, Pathak S. Focal fat spared area in the liver masquerading as hepatic metastasis on F-18 FDG PET imaging. Clin Nucl Med. 2008;33:802–805.PubMedCrossRef Purandare NC, Rangarajan V, Rajnish A, Shah S, Arora A, Pathak S. Focal fat spared area in the liver masquerading as hepatic metastasis on F-18 FDG PET imaging. Clin Nucl Med. 2008;33:802–805.PubMedCrossRef
3.
go back to reference Kim WR, Poterucha JJ, Porayko MK, Dickson ER, Steers JL, Wiesner RH. Recurrence of nonalcoholic steatohepatitis following liver transplantation. Transplantation. 1996;62:1802–1805.PubMedCrossRef Kim WR, Poterucha JJ, Porayko MK, Dickson ER, Steers JL, Wiesner RH. Recurrence of nonalcoholic steatohepatitis following liver transplantation. Transplantation. 1996;62:1802–1805.PubMedCrossRef
4.
go back to reference Burke A, Lucey MR. Non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and orthotopic liver transplantation. Am J Transplant. 2004;4:686–693.PubMedCrossRef Burke A, Lucey MR. Non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and orthotopic liver transplantation. Am J Transplant. 2004;4:686–693.PubMedCrossRef
5.
go back to reference Lim LG, Cheng CL, Wee A, et al. Prevalence and clinical associations of post transplant fatty liver disease. Liver Int. 2007;27:76–80.PubMedCrossRef Lim LG, Cheng CL, Wee A, et al. Prevalence and clinical associations of post transplant fatty liver disease. Liver Int. 2007;27:76–80.PubMedCrossRef
6.
go back to reference Marchetti P, Navalesi R. The metabolic effects of cyclosporin and tacrolimus. J Endocrinol Invest. 2000;23:482–490.PubMed Marchetti P, Navalesi R. The metabolic effects of cyclosporin and tacrolimus. J Endocrinol Invest. 2000;23:482–490.PubMed
7.
go back to reference Dumortier J, Giostra E, Belbouab S, et al. Non-alcoholic fatty liver disease in liver transplant recipients: another story of “seed and soil”. Am J Gastroenterol. 2010;105:613–620.PubMedCrossRef Dumortier J, Giostra E, Belbouab S, et al. Non-alcoholic fatty liver disease in liver transplant recipients: another story of “seed and soil”. Am J Gastroenterol. 2010;105:613–620.PubMedCrossRef
8.
go back to reference Cauble MS, Gilroy R, Sorrell MF, et al. Lipoatrophic diabetes and end-stage liver disease secondary to nonalcoholic steatohepatitis with recurrence after liver transplantation. Transplantation. 2001;71:892–895.PubMedCrossRef Cauble MS, Gilroy R, Sorrell MF, et al. Lipoatrophic diabetes and end-stage liver disease secondary to nonalcoholic steatohepatitis with recurrence after liver transplantation. Transplantation. 2001;71:892–895.PubMedCrossRef
9.
go back to reference Molloy RM, Komorowski R, Varma RR. Recurrent nonalcoholic steatohepatitis and cirrhosis after liver transplantation. Liver Transplant Surg. 1997;3:177–178.CrossRef Molloy RM, Komorowski R, Varma RR. Recurrent nonalcoholic steatohepatitis and cirrhosis after liver transplantation. Liver Transplant Surg. 1997;3:177–178.CrossRef
10.
go back to reference Malik SM, Devera ME, Fontes P, Shaikh O, Sasatomi E, Ahmad J. Recurrent disease following liver transplantation for nonalcoholic steatohepatitis cirrhosis. Liver Transplant. 2009;15:1843–1851.CrossRef Malik SM, Devera ME, Fontes P, Shaikh O, Sasatomi E, Ahmad J. Recurrent disease following liver transplantation for nonalcoholic steatohepatitis cirrhosis. Liver Transplant. 2009;15:1843–1851.CrossRef
11.
go back to reference Yalamanchili K, Saadeh S, Klintmalm GB, Jennings LW, Davis GL. Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease. Liver Transplant. 2010;16:431–439. Yalamanchili K, Saadeh S, Klintmalm GB, Jennings LW, Davis GL. Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease. Liver Transplant. 2010;16:431–439.
12.
go back to reference Barritt ASt, Dellon ES, Kozlowski T, Gerber DA, Hayashi PH. The influence of nonalcoholic fatty liver disease and its associated comorbidities on liver transplant outcomes. J Clin Gastroenterol. 2010. Barritt ASt, Dellon ES, Kozlowski T, Gerber DA, Hayashi PH. The influence of nonalcoholic fatty liver disease and its associated comorbidities on liver transplant outcomes. J Clin Gastroenterol. 2010.
13.
go back to reference Malik SM, deVera ME, Fontes P, Shaikh O, Ahmad J. Outcome after liver transplantation for NASH cirrhosis. Am J Transplant. 2009;9:782–793.PubMedCrossRef Malik SM, deVera ME, Fontes P, Shaikh O, Ahmad J. Outcome after liver transplantation for NASH cirrhosis. Am J Transplant. 2009;9:782–793.PubMedCrossRef
Metadata
Title
Focal Fat Masquerading as Malignancy in the Liver Graft of a Post-Transplant Patient
Authors
Caitlyn M. Patrick
Paul H. Hayashi
Tomasz Kozlowski
Kevin G. Greene
Richard C. Semelka
A. Sidney Barritt IV
Publication date
01-11-2011
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 11/2011
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-011-1739-2

Other articles of this Issue 11/2011

Digestive Diseases and Sciences 11/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine